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Abstract: Baclofen is a racemic mixture that is commonly used for the treatment for spasticity.
However, the optimal dose and dosing interval to achieve effective cerebral spinal fluid (CSF)
concentrations of baclofen are not known. Moreover, it is unclear if there are differences in the ability
of R- or S-baclofen to cross the blood–brain barrier and achieve effective CSF concentrations. We have
validated a liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method
with improved selectivity and sensitivity for the simultaneous quantitation of R- and S-baclofen
and metabolites in plasma and CSF. Protein precipitation by acetonitrile was utilized to obtain an
acceptable recovery of the analytes. The detection and separation of analytes was achieved on a
48 ◦ C-heated Crownpak CR(+) column (150 mm × 4.0 mm, 5µ) with elution using 0.4% formic acid (FA)
in water and 0.4% FA in acetonitrile as the mobile phase running at a flow rate of 1.0 mL/min. Accurate
quantitation was assured by using this MS/MS method with atmospheric pressure chemical ionization
in multiple reaction monitoring (MRM) mode. Therefore, this method is enantioselective, accurate,
precise, sensitive, reliable, and linear from 1 to 1500 ng/mL for baclofen and 2 to 4000 ng/mL for the
metabolites. An additional method was developed to separate racemic baclofen 3-(4-chlorophenyl)-4
hydroxybutyric acid metabolites for individual concentration determination. Both validated methods
were successfully applied to a clinical pharmacokinetic human plasma and CSF study evaluating the
disposition of baclofen and metabolites.
Keywords: LC-MS/MS; baclofen; 3-(4-chlorophenyl)-4 hydroxybutyric acid (CHBA); chiral separation;
CSF; spasticity; pharmacokinetics

1. Introduction
Baclofen (4-amino-3-p-chlorophenyl butyric acid) (Figure 1) is a racemic mixture, comprising
equal amounts of the R- and S-enantiomers and was initially designed as a treatment for seizures in the
late 1960s. Baclofen is now the most commonly prescribed oral medication to treat spasticity of central
origin [1,2], such as cerebral palsy [3], hemi- and tetraplegia [4], and multiple sclerosis [5]. Despite the
widespread use of baclofen, substantial variability exists in exposure and clinical response even when
patients receive similar doses of baclofen [6,7].
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Figure 1.
The chemical
chemical structure
structure of
of (a) baclofen, (b) baclofen-d4, and (c) 3-(4-chlorophenyl)-4
1. The
3-(4-chlorophenyl)-4
hydroxybutyric
hydroxybutyric acid
acid (CHBA)
(CHBA) metabolite.
metabolite.
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2. Results and Discussion
2. Results and Discussion
2.1. Chromatographic and Mass Spectrometric Optimization
2.1. Chromatographic and Mass Spectrometric Optimization
Positive and negative atmospheric pressure chemical ionization (APCI) and electrospray ionization
Positive and negative atmospheric pressure chemical ionization (APCI) and electrospray
(ESI) conditions were tested for optimized MS conditions to detect baclofen and its metabolites.
ionization (ESI) conditions were tested for optimized MS conditions to detect baclofen and its
The signal intensity of baclofen and CHBA metabolites were the highest using the APCI probe in
metabolites. The signal intensity of baclofen and CHBA metabolites were the highest using the APCI
probe in positive and negative mode, respectively. The analytical separation for R and S-baclofen was
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positive and negative mode, respectively. The analytical separation for R and S-baclofen was performed
using a Crownpak CR(+) (4 mm × 150 mm, 5µ) column, as previously described [24]. However, this
method was not able to separate the metabolites S-CHBA and R-CHBA, which co-eluted together
under these conditions. A separate method was developed utilizing a Chiralcel OJ R-RH (2.1 mm ×
150 mm, 5µ) column to separate the R- and S-CHBA metabolites. Moreover, the metabolites were more
readily detected utilizing the APCI probe operated in negative mode (data in supplementary file).
During method optimization, the mass spectra for baclofen and baclofen-d4 (IS) revealed precursor ion
peaks at m/z 214.10, and 218.10, respectively in positive APCI mode. The CHBA metabolite revealed
precursor ion peaks at m/z 213.15 in negative mode APCI. The fragmentation of analytes and IS were
optimized automatically using the auto-optimize function of the LabSolutions software and a stock
solution of each compound. The most abundant parent > product ion with the highest sensitivity for
baclofen, baclofen-d4 , and CHBA metabolite were m/z 214.10 > 151.10 (APCI+), 218.15 > 155.10(APCI+),
and
213.20
> 24,
151.20
(Figure 2), respectively. The final parameters are shown in Table 1. 4 of 12
Molecules
2019,
x FOR(APCI−)
PEER REVIEW

Figure 2. MS product ion spectra of (a) baclofen, (b) baclofen-d4, and (c) CHBA metabolite in +/−
atmospheric
pressure
ionization
mode.
Figure 2. MS
productchemical
ion spectra
of (a) (APCI)
baclofen,
(b) baclofen-d4, and (c) CHBA metabolite in +/–
atmospheric pressure chemical ionization (APCI) mode.

Previous studies extracting baclofen from biomatrices utilized different extraction methods
including solid phase extraction (SPE) [2,21,24], liquid–liquid extraction [25], and protein
precipitation extraction (PPE) [2]. However, SPE [24] in our hands resulted in poor CHBA recovery,
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Table 1. Summary of MS/MS and chromatography parameters for both methods. APCI: atmospheric
pressure chemical ionization, MRM: multiple reaction monitoring.
S-Baclofen R-Baclofen S-CHBA

R-CHBA

S-BAC-d4 R-BAC-d4

MRM transition m/z (Q1→Q3)

214.10 > 151.05

213.15 > 151.10

218.10 > 155.10

MS/MS Ionization

APCI (+) ve Mode

APCI (−) ve Mode

APCI (+) ve Mode

Q1(V)

−30

15

−30

CE(V)

−19

13

−19

Q3(V)

−15

13

−16

R-and S-Baclofen Separation and Racemic CHBA Method:
Column

Crownpak CR(+) 4.00 × 150 mm, 5µ (Part # 27714)

Guard Column:

Crownpak CR(+) 4.00 × 10 mm, 5µ (Part # 27714)

Run Time:

11 min

Mobile Phase

A-0.4% in formic acid water and B: 0.4% formic in acetonitrile

Flow

1 mL/min, Isocratic (86:16, A:B)

Retention time

3.5

5.4

8.7

3.5

5.4

R-and S-CHBA Separation and Racemic Baclofen Method:
Column

Chiralcel OJ R-RH 2.1 × 150 mm, 5µ (Part #17794)

Guard Column:

Phenomex C18

Run Time:

27 min

Mobile Phase

A-0.4% in Formic acid water and B: 0.4% Formic in acetonitrile

Flow

0.1 mL/min, Isocratic (86:16, A:B)

Retention time

5.0

21.0

23.5

5.1

R- and S-baclofen were separated and quantitated using the final mobile phase consisting of
0.4% formic acid (FA) in water and 0.4% FA in acetonitrile (ACN)utilizing a Crownpak CR(+) column.
The total flow rate was 1.0 mL/min, and the column temperature was set to 48 ◦ C, which produced the
best peak shape and no endogenous interference for the R- and S-baclofen enantiomers.
R and S-CHBA metabolites were separated using a Chiralcel OJ R-RH column with 0.4% FA in water
and 0.4% FA in ACN (86:16, v/v) as the mobile phase and a flow rate of 0.1 mL/min. These conditions
resulted in acceptable peak shape for R and S-CHBA metabolites with no interference of endogenous
compounds at the retention time for both baclofen and its CHBA metabolites (Supplementary Figure S1).
Post-column infusion of 0.5% ammonium hydroxide (NH4 OH) in water–ACN (80:20, v/v) was
accomplished using a three-way connector before mass detection to improve ionization for the R- and
S-CHBA metabolites, which utilized negative APCI mode ionization (data not shown) [2].
The retention times for S-baclofen, R-baclofen, S-CHBA, and R-CHBA were 3.5, 5.4, 21.0, and
23.5 min in both assays, respectively.
Previous studies extracting baclofen from biomatrices utilized different extraction methods
including solid phase extraction (SPE) [2,21,24], liquid–liquid extraction [25], and protein precipitation
extraction (PPE) [2]. However, SPE [24] in our hands resulted in poor CHBA recovery, with only
approximately 5% of the metabolite recovered (data not shown). In order to simplify procedures
and improve metabolite recovery, we utilized a PPE method to achieve approximately 90% absolute
recovery for baclofen and CHBA metabolites (Section 2.2.6). The addition of a simple and inexpensive
sample extraction resulted in exhanced recovery and no matrix effect. The human plasma and CSF
mixed with blank plasma both resulted in similar recovery and matrix effect. The human plasma
was used to construct CSF calibration curves and quality controls (QC)s, whereas a CSF real sample
was mixed with 100 uL blank plasma to nullify the potential matrix effects. The same PPE extraction
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method was utilized for both assays. The method is quantitative, validated for both plasma and CSF
samples, and linear from 1 to 1500 ng/mL for baclofen. Our validated method is accurate, precise, and
Molecules 2019, 24, x FOR PEER REVIEW
5 of 12
sensitive, allowing for the routine analysis of baclofen and metabolites in clinical samples [26].
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2.2.3. Calibration Curve and Linearity
2.2.3. Calibration Curve and Linearity
To calculate concentrations for unknown samples, linear regression with and without intercepts
To calculate concentrations for unknown samples, linear regression with and without intercepts
(y = mx + c and y = mx) and 1/y2 weighting
was utilized. The final assay was linear over the
(y = mx + c and y = mx) and 1/y2 weighting was utilized. The final assay was linear over the
concentration range of 1 to 2000 ng/mL for R- and S-baclofen and from 2 to 4000 ng/mL for racemic
concentration range of 1 to 2000 ng/mL for R- and S-baclofen and from 2 to 4000 ng/mL for racemic
CHBA. In the second assay, concentrations ranging from 1 to 2000 ng/mL for R- and S-CHBA and 2
to 4000 ng/mL for racemic baclofen were linear.

2.2.4. Carry-Over
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CHBA. In the second assay, concentrations ranging from 1 to 2000 ng/mL for R- and S-CHBA and 2 to
4000 ng/mL for racemic baclofen were linear.
2.2.4. Carry-Over
There was no significant carry-over effect based on the response of a blank sample injected
following a spiked sample (data not shown).
2.2.5. Accuracy and Precision
The inter-day and intra-day accuracy (% bias) and precision (%RSD) results for the detection
of baclofen and CHBA metabolites in human plasma samples at the lower limit of quantification
(LLOQ), low-quality control (LQC), middle-quality control (MQC), and high-quality control (HQC)
are presented in Table 2. Using a Crownpak column to separate R-and S-baclofen and total CHBA
metabolites, the RSD of inter- and intra-day accuracy values were between −5.2 and 18.4%, and interand intra-day precision values ranged from 1.1 to 16.6% (Table 2).
Table 2. Inter-day and intra-day accuracy (% bias) and precision (%RSD) for baclofen and its metabolite
in human plasma. HQC: high-quality control, LLOQ: lower limit of quantification, LQC: low-quality
control, MQC: middle-quality control.
Conc. (ng/mL)
Theoretical
Conc.
%Biasintra-assay
%Biasinter-assay
% RSDintra-assay
% RSDinter-assay

S-Baclofen
LLOQ

LQC

R-Baclofen

MQC

HQC

LLOQ

LQC

MQC

CHBA (Racemic)
HQC

LLOQ

LQC

MQC

HQC

1
5
500
1500
1
5
500
1500
2
10
1000
3000
ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL
11.1
14.1
7.7
16.6

0.4
−1.3
2.4
4.2

1.7
4.0
1.9
3.9

−1.3
−2.3
1.6
4.3

7.4
7.9
2.1
5.8

0.6
8.9
5.2
8.1

−0.9
0.2
3.6
1.7

−3.4
−3.8
1.1
2.1

6.0
18.4
11.0
12.1

−5.2
4.1
5.0
9.8

2.9
4.2
3.2
5.5

−3.9
−2.3
1.2
3.3

Using a Chiralcel column to separate R- and S-CHBA metabolites and total baclofen, the RSD of
inter-day precision values were between 3.3 and 18.7% with intra-day precision values ranging from
1.7 to 9.7%, which indicated acceptable assay precision (Supplementary Table S1).
2.2.6. Recovery and Matrix Effect
The absolute recoveries were calculated at the LQC, MQC, and HQC concentration as the
mean peak area of an analyte spiked before extraction to the mean peak area of an analyte spiked
post-extraction multiplied by 100. The absolute mean recovery results for S-baclofen, R-baclofen, and
CHBA (racemic) respectively are provided in Table 3. The recovery of IS was found to be 88.1 ± 6.1%
and 86.4 ± 6.4% for S- and R-baclofen-d4 , respectively. In general, baclofen and its metabolite recovery
was approximately 90%.
Table 3. Absolute extraction recoveries and absolute matrix effects of the baclofen and its metabolite
from human plasma and cerebral spinal fluid (CSF) (Mean ± SD, n = 3).
Absolute Extraction Recovery (%)

Absolute Matrix Effect (%)

Bio-Matrix

Analytes

LQC

MQC

HQC

LQC

MQC

HQC

Human plasma

S-baclofen
R-baclofen
Racemic CHBA

94.2 ± 8
99.4 ± 7.7
99.9 ± 9.3

84.8 ± 2.3
99.2 ± 7.7
107.7 ± 7.5

85 ± 6.7
88.6 ± 10.6
109.1 ± 6.2

94.7 ± 7.4
87.7 ± 6.1
96.4 ± 1.7

85.8 ± 3.9
91.4 ± 2.0
96.3 ± 4.9

89.7 ± 7.7
94.7 ± 16.3
100.2 ± 1.5

CSF: Plasma
(1:1)

S-baclofen
R-baclofen
Racemic CHBA

82.2 ± 2.4
95.8 ± 2.1
97.9 ± 9.3

103.0 ± 10.8
94.7 ± 3.2
109.2 ± 0.9

96.8 ± 0.2
97 ± 0.6
101.7 ± 6.4

83.4 ± 4.3
84 ± 3.9
94.5 ± 10.6

88.2 ± 5.3
86.5 ± 1.0
105.2 ± 6.1

89.9 ± 4.4
91.8 ± 5.3
101.9 ± 7.9
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Plasma calibration curve (CC) and QCs to were found to mimic human CSF mixed with 100-µL
blank plasma with similar recovery and matrix effects using analyte/IS peak area ratios. The matrix
effect for all analytes at LQC, MQC, and HQC concentration levels in plasma and CSF were < ±15%
(85.2–105.2%). The IS normalized matrix effect for all analytes were < ±15% (91.9–113.6). The recoveries
of all analytes in the plasma were similar to those in CSF (Table 3), indicating a no-matrix effect for the
study samples. Our result confirms that plasma CC and QCs mimic human CSF mixed with 100-µL
blank plasma, as they have shown similar recovery and matrix effects using analyte/IS peak area ratios.
2.2.7. Stability
R and S-baclofen and racemic CHBA were found to be stable under the conditions tested.
The stability data are provided in Table 4. Overall, in the different stability studies, concentrations of
analytes remained within 15% of the actual corresponding LQC, MQC, and HQC concentrations.
Table 4. Mean stability recoveries of baclofen and its metabolites at different storage conditions in
human plasma.
S-Baclofen

R-Baclofen

CHBA (Racemic)

Measured
Mean Conc.
(ng/mL)

Accuracy
(%)

Measured
Mean Conc.
(ng/mL)

Accuracy
(%)

Measured
Mean Conc.
(ng/mL)

Accuracy
(%)

LQC

4.9 ± 0.3

97.3 ± 6.1

5.0 ± 0.5

99.4 ± 9.1

10.7 ± 1.1

106.9 ± 11.0

HQC

1520.0 ± 32.3

101.3 ± 2.1

1490.1 ± 18.8

99.3 ± 1.3

2771.2 ± 829.0

104.4 ± 2.2

LQC

5.0 ± 0.3

100.5 ± 6.6

5.3 ± 0.4

105.9 ± 8.1

9.8 ± 0.9

98.1 ± 8.6

HQC

1551.2 ± 19.9

103.4 ± 1.3

1511.5 ± 10.7

100.8 ± 0.7

3148.8 ± 47.7

105.0 ± 1.6

Long-term stability
(−80 ◦ C, 40 days)

LQC

4.6 ± 0.2

92.1 ± 4.2

4.7 ± 0.2

94.3 ± 3.1

10.0 ± 1.4

100.4 ± 13.6

HQC

1533.1 ± 1.9

102.2 ± 0.1

1473.2 ± 22.4

98.3 ± 1.5

1533.1 ± 28.1

107.0 ± 0.9

Auto-sampler
stability (4 ◦ C, 72 h)

LQC

5.3 ± 0.2

105.9 ± 3.6

5.4 ± 0.1

108.6 ± 2.1

5.3 ± 3.1

98.2 ± 0.1

HQC

1492.8 ± 7.0

99.5 ± 0.4

1501 ± 2.8

100.2 ± 0.2

1492.8 ± 118.0

100.8 ± 4.0

LQC

5.3 ± 0.2

105.4 ± 3.5

5.6 ± 0.1

111.8 ± 1.1

5.3 ± 3.0

107.6 ± 0.9

Storage Conditions

Conc.

Bench-top stability
(20 ◦ C, up to 6 h)
Freeze–thaw stability
(−80 ◦ C, up to three
cycles)

Processed Samples’
long-term stability
(−80 ◦ C, 40 days)

2.2.8. Application of the Method for Clinical Sample Analysis
Therapeutic concentrations of baclofen are considered to be 80–400 ng/mL in plasma [27]. Baclofen
oral doses between 30 to 90 mg daily are related to total baclofen plasma concentrations of 68 to
650 ng/mL [28]. The validated LC-MS/MS method was utilized to determine the concentration of
S-baclofen, R-baclofen, and its CHBA metabolite in plasma and CSF following single oral baclofen doses
of 15–30 mg. The plasma concentrations of R- and S-baclofen (median: range) were detected during
therapy: 54.8 (6.4–334.0) ng/mL and 59.7 (5.6–246.4) ng/mL, respectively. The CSF concentrations of Rand S-baclofen detected during therapy ranges were 1.7–20.8 ng/mL and 1.4–14.4 ng/mL, respectively.
The ratio of plasma to CSF for R-baclofen and S-baclofen ranges were 3.5–35.2 and 4.0–33.9, respectively.
The R-CHBA metabolite was not detected in plasma or CSF samples (Supplementary Figure S1), while
the S-CHBA metabolite ranges were 8.8–48.6 ng/mL and 1.3–15.4 ng/mL in plasma and CSF, respectively.
The present bioanalytical method is useful for the therapeutic monitoring of baclofen therapy
and evaluating strategies to individualize baclofen therapy. Drowsiness is a common side effect of
baclofen therapy and is suggested to be dose-dependent. The evaluation of baclofen and metabolite
concentrations along with assessments of efficacy and toxicity will be important to further improve
the use of baclofen. The overall goal of treatment is to individualize baclofen therapy to improve the
therapeutic response while minimizing systemic toxicities. While the study presented here provides
a useful tool to monitor baclofen therapy, the limited number of subjects limits our conclusions.
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Additional studies with a larger number of patients will be crucial to the development of individualized
baclofen therapy.
3. Materials and Methods
3.1. Chemicals and Materials
S-baclofen, R-baclofen, S-CHBA, R-CHBA, and baclofen-d4 of pharmaceutical grade were obtained
from Toronto Research Chemicals (Toronto, Ontario, Canada). Mobile phase solutions were purchased
from Fisher Scientific (Fair Lawn, NJ, USA) including HPLC-grade methanol (MeOH), acetonitrile
(ACN), and formic acid (FA). Centrifuge tube filters were obtained from Corning Co. (Corning, NY,
USA). A water purification system (ThermoFisher Scientific, Grand Island, NY, USA) was utilized
for ultrapure water. Other reagents were purchased from standard chemical suppliers and were of
analytical grade or higher.
3.2. Liquid Chromatographic and Mass Spectrometric (LC/MS) Conditions
A Shimadzu Nexera Ultra high-performance liquid chromatography (UHPLC) system (Shimadzu
Scientific Instruments, Columbia, MD) was used for chromatographic separation and included a
binary pump system (LC-30 AD), an auto-sampler (SIL-30AC) and a column oven (CTO-30AS).
Mass spectrometric detection was performed using a LC-MS/MS 8060 system (Shimadzu Scientific
Instruments, Columbia, MD, USA) and an atmospheric pressure chemical ionization (APCI) probe.
Two methods were validated to separate and quantitate all four compounds of interest. One
method to separate both R-and S-isomers for baclofen and racemic CHBA metabolite (both R and S
isomers) and a second method to quantitate R-CHBA and S-CHBA and racemic baclofen.
R- and S-baclofen separation and racemic CHBA assay: All chromatographic separations were
performed with a Crownpak CR(+) column (4 mm × 150 mm, 5µ; Daicel Chemical Industries, Ltd.,
Osaka, Japan) equipped with a guard column (Crownpak CR(+) 4.00 × 10 mm, 5µ). The system was
calibrated in isocratic mode with a mobile phase consisting of 0.4% FA in water-0.4% FA in acetonitrile
(ACN) (84:16, v/v) at a flow rate of 1.0 mL/min along with a column oven heated to 48 ◦ C. The total run
time was 11 min. The injection volume of all samples was 20 µL.
Post-column infusion of 0.5% ammonium hydroxide (NH4 OH) in water–ACN (80:20, v/v) at
0.1 mL/min was performed using a three-way connector before mass detection. Detailed parameters
about each method and comparison are shown in Table 1.
The MS parameters were optimized using the auto-optimization method as implemented in
LabSolutions software Version 5.6 (Shimadzu Scientific, Inc., Columbia, MD, USA). The final parameters
for each analyte and IS are shown in Table 1.
3.3. Preparation of Stock, Calibration Standards, and Quality Control Samples
Stock solutions of R- and S-baclofen, R-CHBA, and S-CHBA were prepared by dissolving 1 mg of
each compound into 1 mL of water. The stock solutions were transferred to an Eppendorf vial and
stored at −20 ◦ C for future use.
For the quantitation of R- and S-baclofen and R-CHBA, and S-CHBA, these four stock solutions
were further diluted with 50% methanol in water to obtain a concentration of 20 µg/mL, which was
then further diluted respectively for the preparation of working standard solutions. The calibration
standards (CCs) were individually prepared by spiking 20 µL of mixed working standard solution
into 200 µL of plasma to obtain a concentration ranging from 1 to 2000 ng/mL (1, 2, 5, 10, 50, 200,
1000, and 2000 ng/mL) for R- and S-baclofen. For racemic CHBA, the concentration ranged from
2 to 4000 ng/mL (2, 4, 10, 20, 100, 400, 2000, and 4000 ng/mL). Apart from CCs, five replicates of
each QC concentration were also prepared at the same time. QC samples were prepared at 1 ng/mL
(lower limit of quantification, LLOQ), 5 ng/mL (low-quality control, LQC), 500 ng/mL (middle-quality
control, MQC), and 1500 ng/mL (high-quality control, HQC) for R- and S-baclofen. The corresponding
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concentration for CHBA was doubled due to its racemic mixture. Plasma was used to construct CSF
calibration curves and QCs, whereas CSF samples were mixed with 100 uL of blank plasma to nullify
any potential matrix effect.
For the internal standard, 1 mg/mL stock solution of baclofen-d4 (racemic) was prepared by
dissolving 1 mg in 1 mL of water. The sample was transferred to an Eppendorf vial and stored at
−20 ◦ C for future use. When preparing working IS stock solution, the baclofen-d4 was diluted with
50% methanol to make a 5 µg/mL solution.
3.4. Plasma and CSF Sample Preparation
The extraction of baclofen and metabolites was performed using a simple protein precipitation
extraction (PPE) method. Briefly, 200 µL of blank human plasma, CSF, QC, or study sample was
transferred into a 1.5-mL polypropylene (PP) tube, and CCs were spiked with 20 µL of working stock
solution as well as 20 µL of IS working solution (baclofen-d4 , 5 µg/mL). Ice-cold ACN (1 mL) was
added to each sample, and the solution was mixed on a vortex mixer for 30 s. Subsequently, 100 µL of
0.1% formic acid in water was added, and the mixture was vortexed for 2 min and then centrifuged at
18,000× g for 10 min at 4 ◦ C. The supernatant (approximately 950 µL) was transferred to a 13 × 100 mm
glass tube and evaporated under nitrogen at 40 ◦ C. The dried sample was reconstituted with 100 µL of
0.1% FA–MeOH (85:15, v/v), vortexed for 30 s, and centrifuged again at 18,000× g for 15 min at 4 ◦ C,
after which the supernatant (approximately 80 uL) was transferred to an autosampler vial.
3.5. Assay Validation
The developed LC-MS/MS assay for R- and S-baclofen separation and racemic CHBA was fully
validated in plasma, and the assay for R- and S-CHBA separation was validated for sensitivity,
selectivity, accuracy, and precision (data in supplementary files) in plasma, according to the current
FDA guidelines [29].
The assay sensitivity was evaluated by calculating the accuracy and precision (A&P) at an
assigned LLOQ with ±20% of nominal concentration. Additionally, sensitivity was determined via the
signal-to-noise ratio (S/N) of the analyte response in the calibration standards, which was required to
be greater than three for the LOD and 10 for the LLOQ.
Assay selectivity and specificity were determined by comparing the results of six different blank
human plasma samples with those of R-baclofen, S-baclofen, R-CHBA, S-CHBA, and the IS-spiked
sample for the assessment of potential interferences with endogenous substances at the retention time
of analytes or IS.
The peak area ratio (analyte/IS) versus concentration for all analytes was plotted to generate
calibration curves for each analyte. The calibration curve consisted of 12 data points, including a blank
sample (no analyte or IS), a zero calibrator (blank + IS), and 10 CCs. All standard concentrations were
required to be within ±15% standard deviation (SD) from the nominal value with the exception at
LLOQ, which was set at ±20%.
The carry-over effect was determined by injecting two blank samples (no analyte or IS) following
an HQC sample.
The method was validated for intra-day accuracy and precision by the analysis of five replicates
of the QC samples injected on the same day. To assess inter-day accuracy and precision, five samples at
each QC concentration were injected daily for three separate days. Precision was defined as the percent
relative standard deviation (%RSD) with an acceptance criteria of ±15% (except for ±20% at LLOQ).
Accuracy was defined as the percent bias (% bias) with the same acceptance criteria as precision.
3.6. Recovery and Matrix Effect
The peak area of R and S-baclofen, IS, and racemic metabolites in extracted samples (plasma and
CSF mixed with blank plasma, 1:1) at three different QC concentrations (i.e., LQC, MQC, and HQC)
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were compared to the peak area or peak area ratio obtained for equivalent concentrations for each
analyte in post-extracted samples..
To assess the effect of the matrix on analyte response, blank human plasma and CSF mixed
with blank plasma were processed, and the dry post-extract was spiked with analyte and prepared
equivalent to the QCs. The average of peak area from all the analytes spiked in the blank matrix was
compared to the response for QCs prepared in reconstitution solvent. The absolute matrix effect (ME)
and IS normalized ME were calculated as described in Equations (1) and (2).
ME =

Mean Peak area o f analyte spiked post-extraction
× 100
Mean Peak area o f analyte in Solvent

IS normalized ME =

Mean Peak area ratio o f analyte/IS spiked post-extraction
× 100
Mean Peak area ratio o f analyte/IS in Solvent

(1)

(2)

3.7. Stability
Baclofen and CHBA metabolite stability in human plasma samples was determined for bench-top
storage (20 ◦ C for up to 6 h), three freeze–thaw cycles (room temperature to −80 ◦ C to room temperature),
long-term stability (−80 ◦ C for 40 days) before and after processing the samples, and auto-sampler
stability (4 ◦ C for 72 h). The sample concentration for all analytes under each individual condition was
tested, and the mean values for accuracy and precision were calculated.
3.8. Clinical Study and Therapeutic Drug Monitoring
Biospecimens were obtained from patients (<20 years of either sex) presenting with spastic or
dystonic cerebral palsy who were having their CSF space accessed as part of routine clinical care at the
Department of Rehabilitation Medicine at Children’s Mercy-Kansas City. All specimens were obtained
with informed permission/assent. The protocol was approved by the institutional ethics committee
(approval number 17120739). Each parent or legal guardian provided permission for their child to
participate in this study and were provided assent for participation. Both the parent/guardian and
the participant were informed of the objectives, nature, and potential risks of the study. Participants
received their current oral dose of baclofen, ranging from 15 to 30 mg per dose. Blood samples (2 mL
in 3.8% tri-Sodium Citrate 9:1, v/v) were obtained at the same time as CSF samples (±5 min). The blood
samples were centrifuged at 2000× g at 4 ◦ C for 10 min to separate the plasma. All plasma and CSF
samples were stored in sealed tubes at −80 ◦ C until analysis. Two participants provided paired clinical
specimens and were evaluated as part of method development.
4. Conclusions
We have developed two reproducible and efficient LC-MS/MS methods for separating and
quantitating racemic baclofen and its racemic CHBA metabolites, respectively. Compared to previous
studies, we have improved the recovery of the metabolites during sample processing. In addition,
our results confirmed that there is no R-CHBA metabolite formed in the CSF or that crosses from the
plasma to CSF. Therefore, a single method to determine racemic baclofen and the CHBA metabolite
was also developed during this study and is sufficient to monitor the S-CHBA metabolite in the
CSF, as no R-CHBA was observed in CSF samples. Baclofen plasma-to-CSF concentration ratios
were also determined to be approximately 3.8–34.6, which could be beneficial to evaluate therapeutic
effect without performing an invasive lumbar puncture. This method will help to understand the
biodistribution and pharmacodynamic effects of baclofen and metabolites, potentially improving the
efficacy and safety of baclofen therapy.
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Supplementary Materials: The following are available online, Figure S1: Representative MRM ion-chromatograms
of (a) blank plasma using the conditions for racemic baclofen showing interfering peak at 4.5 min, (b) plasma spiked
with baclofen (rt, 5.0 min, 10 ng/mL), (c) extracted patient sample, (d) blank plasma using the conditions for CHBA
metabolite, (e) plasma spiked with CHBA metabolite showing the two isomers (S-CHBA 21.0 min and R-CHBA
23.5 min, at 5 ng/mL), (f) extracted patient sample showing only the S-CHBA metabolite is present in plasma,
(g) blank plasma using the conditions for baclofen-d4 showing interfering peak at 4.5 min, (h) plasma spiked with
IS (baclofen-d4; rt, 5.0 min, 1000 ng/mL), (i) extracted patient sample spiked with IS (baclofen-d4). Table S1: Intra
and inter-day precision (%RSD) and accuracy (% bias) for baclofen and its metabolites in human plasma.
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